Search Results - "Costa, Daniel B"

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications by Yasuda, Hiroyuki, MD, Kobayashi, Susumu, MD, Costa, Daniel B, Dr

“…Summary Lung cancer is the leading cause of cancer-related death. The identification of epidermal growth factor receptor (EGFR) somatic mutations defined a…”
Get full text

What Role Do Intelligent Reflecting Surfaces Play in Multi-Antenna Non-Orthogonal Multiple Access? by Sena, Arthur S. de, Carrillo, Dick, Fang, Fang, Nardelli, Pedro H. J., Costa, Daniel B. da, Dias, Ugo S., Ding, Zhiguo, Papadias, Constantinos B., Saad, Walid

“…Massive multiple-input multiple-output (MIMO) and non-orthogonal multiple access (NOMA) are two key techniques for enabling massive connectivity in future…”
Get full text

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches by Shea, Meghan, Costa, Daniel B., Rangachari, Deepa

“…Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLCs). Expert consensus has…”
Get full text

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints by Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.

“…Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung…”
Get full text

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib by Costa, Daniel B, Kobayashi, Susumu, Pandya, Shuchi S, Yeo, Wee-Lee, Shen, Zhongzhou, Tan, Weiwei, Wilner, Keith D

Get full text

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer by Shaw, Alice T, Ou, Sai-Hong I, Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J, Salgia, Ravi, Riely, Gregory J, Varella-Garcia, Marileila, Shapiro, Geoffrey I, Costa, Daniel B, Doebele, Robert C, Le, Long Phi, Zheng, Zongli, Tan, Weiwei, Stephenson, Patricia, Shreeve, S. Martin, Tye, Lesley M, Christensen, James G, Wilner, Keith D, Clark, Jeffrey W, Iafrate, A. John

“…About 1% of non–small-cell lung cancers have ROS1 rearrangements. This oncogene is inhibited by crizotinib. In a cohort of 50 patients with ROS1 -rearranged…”
Get full text

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma by Rangachari, Deepa, VanderLaan, Paul A, Shea, Meghan, Le, Xiuning, Huberman, Mark S, Kobayashi, Susumu S, Costa, Daniel B

“…Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor…”
Get more information

Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study by Camidge, D Ross, Dr, Bang, Yung-Jue, Prof, Kwak, Eunice L, MD, Iafrate, A John, MD, Varella-Garcia, Marileila, Prof, Fox, Stephen B, Prof, Riely, Gregory J, MD, Solomon, Benjamin, MBBS, Ou, Sai-Hong I, MD, Kim, Dong-Wan, Prof, Salgia, Ravi, Prof, Fidias, Panagiotis, MD, Engelman, Jeffrey A, MD, Gandhi, Leena, MD, Jänne, Pasi A, MD, Costa, Daniel B, MD, Shapiro, Geoffrey I, MD, LoRusso, Patricia, DO, Ruffner, Katherine, MD, Stephenson, Patricia, ScD, Tang, Yiyun, PhD, Wilner, Keith, PhD, Clark, Jeffrey W, MD, Shaw, Alice T, MD

“…Summary Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in…”
Get full text

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK by SHAW, Alice T, YEAP, Beow Y, SETTLEMAN, Jeffrey, KOBAYASHI, Susumu, MARK, Eugene J, RODIG, Scott J, CHIRIEAC, Lucian R, KWAK, Eunice L, LYNCH, Thomas, IAFRATE, A. John, MINO-KENUDSON, Mari, DIGUMARTHY, Subba R, COSTA, Daniel B, HEIST, Rebecca S, SOLOMON, Benjamin, STUBBS, Hannah, ADMANE, Sonal, MCDERMOTT, Ultan

“…The EML4-ALK fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLC). To aid in identification and…”
Get full text

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer by Yasuda, Hiroyuki, Park, Eunyoung, Yun, Cai-Hong, Sng, Natasha J, Lucena-Araujo, Antonio R, Yeo, Wee-Lee, Huberman, Mark S, Cohen, David W, Nakayama, Sohei, Ishioka, Kota, Yamaguchi, Norihiro, Hanna, Megan, Oxnard, Geoffrey R, Lathan, Christopher S, Moran, Teresa, Sequist, Lecia V, Chaft, Jamie E, Riely, Gregory J, Arcila, Maria E, Soo, Ross A, Meyerson, Matthew, Eck, Michael J, Kobayashi, Susumu S, Costa, Daniel B

“…Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine…”
Get more information

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis by Shaw, Alice T, Dr, Yeap, Beow Y, ScD, Solomon, Benjamin J, MD, Riely, Gregory J, MD, Gainor, Justin, MD, Engelman, Jeffrey A, MD, Shapiro, Geoffrey I, MD, Costa, Daniel B, MD, Ou, Sai-Hong I, MD, Butaney, Mohit, BS, Salgia, Ravi, Prof, Maki, Robert G, MD, Varella-Garcia, Marileila, Prof, Doebele, Robert C, MD, Bang, Yung-Jue, Prof, Kulig, Kimary, PhD, Selaru, Paulina, MSPH, Tang, Yiyun, PhD, Wilner, Keith D, PhD, Kwak, Eunice L, MD, Clark, Jeffrey W, MD, Iafrate, A John, MD, Camidge, D Ross, MD

“…Summary Background ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK…”
Get full text

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer by SEQUIST, Lecia V, VON PAWEL, Joachim, RAMLAU, Rodryg, ARTHUR, Susan, GORBACHEVSKY, Igor, SCHWARTZ, Brian, SCHILLER, Joan H, GARMEY, Edward G, AKERLEY, Wallace L, BRUGGER, Wolfram, FERRARI, Dora, YINPU CHEN, COSTA, Daniel B, GERBER, David E, ORLOV, Sergey

“…c-MET (MET) receptor activation is associated with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in…”
Get full text

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas by Jorge, Susan E, Lucena-Araujo, Antonio R, Yasuda, Hiroyuki, Piotrowska, Zofia, Oxnard, Geoffrey R, Rangachari, Deepa, Huberman, Mark S, Sequist, Lecia V, Kobayashi, Susumu S, Costa, Daniel B

“…exon 20 insertions account for up to 10% of all mutations in lung adenocarcinomas, representing the third most common cluster of mutations. The management of…”
Get full text

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors by Kobayashi, Susumu, Canepa, Hannah M, Bailey, Alexandra S, Nakayama, Sohei, Yamaguchi, Norihiro, Goldstein, Michael A, Huberman, Mark S, Costa, Daniel B

“…Non-small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors…”
Get more information

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer by Yasuda, Hiroyuki, de Figueiredo-Pontes, Lorena L, Kobayashi, Susumu, Costa, Daniel B

“…Most clinically available small-molecule kinase inhibitors are multi-targeted and can inhibit multiple kinases. Our driving hypothesis was that one of these…”
Get more information

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples by Rangachari, Deepa, To, Ciric, Shpilsky, Jason E, VanderLaan, Paul A, Kobayashi, Susumu S, Mushajiang, Mierzhati, Lau, Christie J, Paweletz, Cloud P, Oxnard, Geoffrey R, Jänne, Pasi A, Costa, Daniel B

“…Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation…”
Get more information

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer by Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro, Naoki, Katsuhiko, Costa, Daniel B, Kobayashi, Susumu S, Betsuyaku, Tomoko, Soejima, Kenzo

“…EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell lung cancer (NSCLC). Over the last decade, multiple EGFR tyrosine kinase…”
Get full text

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? by Sehgal, Kartik, Costa, Daniel B, Rangachari, Deepa

“…Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019 (COVID-19). Recurrent hospital visits and hospital…”
Get full text

Analysis and Optimization of Tail-Biting Spatially Coupled Protograph LDPC Codes for BICM-ID Systems by Yang, Zhaojie, Fang, Yi, Zhang, Guohua, Lau, Francis C. M., Mumtaz, Shahid, da Costa, Daniel B.

“…As a typical example of bandwidth-efficient techniques, bit-interleaved coded modulation with iterative decoding (BICM-ID) provides desirable spectral…”
Get full text

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway by Nguyen, Kim-Son H, Kobayashi, Susumu, Costa, Daniel B

“…Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor ( EGFR ) mutations (exon 19 deletions or L858R)…”
Get full text